IL139683A0 - Composition for the induction of a tumour-specific immune response, methods for its production and use of the composition for the treatment of neoplasia - Google Patents

Composition for the induction of a tumour-specific immune response, methods for its production and use of the composition for the treatment of neoplasia

Info

Publication number
IL139683A0
IL139683A0 IL13968399A IL13968399A IL139683A0 IL 139683 A0 IL139683 A0 IL 139683A0 IL 13968399 A IL13968399 A IL 13968399A IL 13968399 A IL13968399 A IL 13968399A IL 139683 A0 IL139683 A0 IL 139683A0
Authority
IL
Israel
Prior art keywords
composition
production
tumor
neoplasia
tumour
Prior art date
Application number
IL13968399A
Other languages
English (en)
Original Assignee
Immunogenec Biotechnologie Gmb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogenec Biotechnologie Gmb filed Critical Immunogenec Biotechnologie Gmb
Publication of IL139683A0 publication Critical patent/IL139683A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13968399A 1998-05-15 1999-05-17 Composition for the induction of a tumour-specific immune response, methods for its production and use of the composition for the treatment of neoplasia IL139683A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19821925A DE19821925A1 (de) 1998-05-15 1998-05-15 Verfahren zur Herstellung einer Zusammensetzung zur Induktion einer tumorspezifischen Immunantwort, sowie Verwendung der Zusammensetzung zur Behandlung von Neoplasien
EP9903353 1999-05-14
PCT/EP1999/003380 WO1999059624A2 (de) 1998-05-15 1999-05-17 Zusammensetzung zur induktion einer tumorspezifischen immunantwort, verfahren zu deren herstellung sowie verwendung der zusammensetzung zur behandlung von neoplasien

Publications (1)

Publication Number Publication Date
IL139683A0 true IL139683A0 (en) 2002-02-10

Family

ID=7867943

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13968399A IL139683A0 (en) 1998-05-15 1999-05-17 Composition for the induction of a tumour-specific immune response, methods for its production and use of the composition for the treatment of neoplasia

Country Status (9)

Country Link
EP (2) EP1077720B1 (xx)
AT (1) ATE222772T1 (xx)
AU (1) AU764390B2 (xx)
CA (1) CA2328057A1 (xx)
DE (2) DE19821925A1 (xx)
DK (1) DK1077720T3 (xx)
ES (1) ES2181444T3 (xx)
IL (1) IL139683A0 (xx)
WO (1) WO1999059624A2 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058968A1 (de) * 2002-12-23 2004-07-15 Apalexo Biotechnologie Gmbh Reinigung rekombinanter filamentöser bakteriophagen mittels affinitätschromatografie zur erhöhung der immunogenität und wirkung von phagenimpfstoffen
CN114907472A (zh) * 2022-04-07 2022-08-16 武汉爱博泰克生物科技有限公司 一种精准复制抗体的方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
NZ219192A (en) * 1986-02-07 1991-10-25 Oncogen Peptides related to p97 melanoma-associated peptide, recombinant virus and vaccines
GB9022190D0 (en) * 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Also Published As

Publication number Publication date
ES2181444T3 (es) 2003-02-16
AU764390B2 (en) 2003-08-14
DE59902472D1 (de) 2002-10-02
WO1999059624A3 (de) 2000-01-27
DK1077720T3 (da) 2004-03-22
ATE222772T1 (de) 2002-09-15
AU4144299A (en) 1999-12-06
EP1214942A2 (de) 2002-06-19
EP1077720A2 (de) 2001-02-28
EP1077720B1 (de) 2002-08-28
WO1999059624A2 (de) 1999-11-25
CA2328057A1 (en) 1999-11-25
DE19821925A1 (de) 1999-11-18
EP1214942A3 (de) 2002-10-02

Similar Documents

Publication Publication Date Title
GB2320716B (en) Improvements in or relating to starch content of plants
DE69924826D1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
HK1044798A1 (en) Her-2/neu fusion proteins.
EP0681585A4 (en) FACTORS ASSOCIATED TO TATA-BINDING PROTEINS, NUCLEIC ACIDS ENCODING TAFS AND METHODS FOR USE THEREOF.
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO1998021343A8 (en) Genes encoding telomerase proteins
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO2002012341A3 (en) Her-2/neu fusion proteins
EP1005540A4 (en) IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
EP0804609A4 (en) NEW GENES OF RESPONSE p53
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
WO1997003635A3 (en) P16 expression constructs and their application in cancer therapy
ATE345819T1 (de) Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung
WO2003085087A8 (en) Modified cea nucleic acid and expression vectors
EP0857780A4 (en) NOVEL PROTEINS SPECIFICALLY EXPRESSED IN LIVER CANCER, GENES ENCODING THESE PROTEINS, ANTIBODIES ACTIVE AGAINST THESE PROTEINS AND METHOD FOR DETECTING THE EXPRESSION OF THESE PROTEINS
IL139683A0 (en) Composition for the induction of a tumour-specific immune response, methods for its production and use of the composition for the treatment of neoplasia
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
HUP9901786A2 (hu) Eljárás helypreferált rákos áttétképződéssel kapcsolatos gének azonosítására immuno-mágneses sejtszeparáció felhasználásával
DE3882455D1 (de) Verfahren zur herstellung von proteinen in loeslicher form.
FR2709132B1 (fr) Fragment d'ADN portant le gène codant pour l'enzyme de fragmentation du N-acétylhéparosane et les séquences adjacentes permettant son expression, enzyme recombinée et son utilisation.
EP0960128A4 (en) Gene product overexpressed in cancer cells
WO1993018151A1 (fr) Element transposable originaire d'une bacterie du genre brevibacterium
WO2000053785A3 (en) Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins